Press releases

Stockholm, December 29, 2025 – Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on difficult-to-treat cancers, today announces new research demonstrating that Pepaxti (melflufen) maintains its anti-myeloma activity in patients with high-risk genetic features, including deletion 17p (del(17p)) and TP53 mutations. These abnormalities are known to be linked to more aggressive disease being less responsive to treatment. The data has been published in an article in Experimental Hematology & Oncology

Stockholm – November 21, 2025 – Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on difficult-to-treat cancers, today announces that the composition of the Nomination Committee has been established

Stockholm – November 11, 2025 – Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on difficult-to-treat cancers, today announces that a panel of leading multiple myeloma experts has published clinical recommendations for the optimal use of melflufen (branded in Europe as Pepaxti) in Annals of Hematology. The review article provides practical guidance on patient selection, dosing, and management, reinforcing Pepaxti’s role as an important treatment option for patients with relapsed, refractory multiple myeloma (RRMM)

Stockholm – November 5, 2025 – Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on difficult-to-treat cancers, today publishes the report for the third quarter 2025

Stockholm – November 3, 2025 – Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on difficult-to-treat cancers, today announces that a collaborative study within the Eurostars funded project NKENGAGE has been accepted as a poster and will be presented at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition, taking place in San Diego, California, between December 6–9, 2025

Stockholm – October 31, 2025 – Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on difficult-to-treat cancers, today announces that the number of votes in Oncopeptides has changed as a result of a conversion of 356,035 class C shares in Oncopeptides to 356,035 ordinary shares, to deliver ordinary shares to participants in Oncopeptides’ incentive program Board SHP 2024

Stockholm – October 29, 2025 – Oncopeptides AB (publ), a biotech company focused on difficult-to-treat cancers, will publish the report for the third quarter 2025, at 08:00 CET on November 5, 2025

Stockholm, October 22, 2025 – Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO) will host a Capital Markets Update on November 13, 2025, from 09:00 to 12:00 CET. The event will be broadcast live online from the Stockholm, offering shareholders and potential investors an in-depth look at the company’s strategic direction and its expanding role in the evolving treatment landscape for multiple myeloma and beyond

Stockholm – October 16, 2025 – Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on difficult-to-treat cancers, today announces the publication of three case reports in the Journal of Cancer Research and Clinical Oncology, demonstrating long-lasting clinical responses to melflufen (branded in Europe as Pepaxti) in patients with relapsed or refractory multiple myeloma (RRMM)

Oncopeptides AB (publ) (“Oncopeptides”) (Nasdaq Stockholm: ONCO), a biotech company focused on difficult-to-treat cancers, today announces that the company has resolved on an issue of warrants in order to fulfil Oncopeptides’ obligations under the existing loan agreement with the European Investment Bank (the “EIB”)